Preserving renal function in adults with hypertension and diabetes: A consensus approach

American Journal of Kidney Diseases

Volumn 36, Issue 3, 2000, Pages 646-661

  Bakris, G L ^a   Williams, M ^a   Dworkin, L ^a   Elliott, W J ^a   Epstein, M ^a   Toto, R ^a   Tuttle, K ^a   Douglas, J ^a   Hsueh, W ^a   Sowers, J ^a   Willis, K ^a  

^a NATIONAL KIDNEY FOUNDATION   (United States)

Author keywords

Albuminuria; Diabetes; Guidelines; Hypertension; Nephropathy; Proteinuria

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE MARKER; DISEASE PREDISPOSITION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MORTALITY; PROTEINURIA; RISK FACTOR; TREATMENT PLANNING;

EID: 0033852481     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.16225     Document Type: Article

References (97)

1. Risk stratification in hypertension: New insights from the Framingham Study
2. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
3. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
4. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
5. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease
6. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: Data from the health examination surveys, 1960 to 1991
7. Clinical Practice Recommendations 1999
8. Risk factors for nephropathy in type 2 diabetes mellitus
9. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM
10. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI)
11. A curriculum for the training and certification of blood pressure measurement for health care providers
12. Human blood pressure determination by sphygmomanometry
13. Early predictors of 15-year end-stage renal disease in hypertensive patients
14. Blood pressure and end-stage renal disease in men
15. The diastolic blood pressure in systolic hypertension
16. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study
17. White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy
18. Benefits of combination antihypertensive therapy in progressive chronic renal failure
19. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29
20. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study
21. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients
22. ACE inhibitor-associated elevations in serum creatinine: Is this a cause for concern?
23. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The HOT Study Group
24. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38
25. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
26. The 1999 Canadian recommendations for the management of hypertension. On behalf of the Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension
27. Achievement and safety of a low BP goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group
28. Maximizing Cardio-renal Benefits: Achieve Blood Pressure Goals
29. Aggressive blood pressure control may eliminate racial disparity in hypertensive renal disease
30. End-stage renal disease in African-American and white men. 16-year MRFIT findings
31. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
32. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators
33. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group
34. J-curve not burned off by HOT study. Hypertension Optimal Treatment
35. The prognostic significance of blood pressure in the elderly
36. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study
37. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee
38. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus Results of the HOPE study and MICRO-HOPE substudy
39. Newer approaches to antihypertensive therapy: Use of fixed-dose combination therapy
40. Therapeutic challenges in the obese, diabetic patient with hypertension
41. Efficacy of diuretics and beta blockers in diabetic hypertensive patients
42. Hypertension and antihypertensive therapy and the risk factors for the type 2 diabetes mellitus
43. Carvedilol
44. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial
45. Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta-blocker propranolol and their combination on haemodynamics in hypertension
46. Renal disease and hypertension in non-insulin dependent diabetes mellitus
47. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM
48. Circadian variation and triggering of cardiovascular events
49. Aortic plaque morphology and vascular events: A follow-up study in patients with ischemic stroke. FAPS investigators. French study of aortic plaques in stroke
50. Circadian variation in the timing of stroke onset: A meta-analysis
51. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group
52. Nephropathy in patients with type 2 diabetes mellitus
53. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies
54. The renoprotective effect of antihypertensive drugs
55. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
56. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients
57. Cost-effectiveness of the new lower blood pressure goal of JNC VI for diabetic hypertensives
58. Proteinuria, Albuminuria, Risk Assessment, Detection, Elimination (PARADE): A position paper of the National Kidney Foundation
59. Atherosclerosis profile and microalbuminuria in essential hypertension
60. Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study
61. Urinary albumin excretion. An independent predictor of ischemic heart disease
62. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal failure in proteinuric, non-diabetic nephropathy. The GISEN group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)
63. Remission of nephrotic range proteinuria in type 1 diabetes. Collaborative Study Group
64. Calcium channel blockers versus other antihypertensive therapies on progression of non-insulin-dependent diabetes mellitus associated nephropathy
65. Remission of nephrotic syndrome in type 1 diabetes: Long term follow-up of patients in the Captopril Study
66. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria
67. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans
68. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
69. Effects of angiotensin-converting enzyme inhibitors, calcium channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in non-insulin-dependent diabetes mellitus patients with hypertension
70. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
71. Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study
72. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group
73. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
74. Comparative effects of an ACE inhibitor and an angiotensin receptor blocker on potassium homeostasis in high risk patients
75. Cost-effectiveness of combination therapy
76. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension
77. Verapamil and nifedipine in combination for the treatment of hypertension
78. Influence of heart rate on mortality among persons with hypertension: The Framingham Study
79. ACE inhibition normalizes renal size and microalbuminuria in normotensive insulin dependent diabetic patients
80. Diabetic hypertension: Barriers to effective control
81. Sexual dysfunction with antihypertensive therapy
82. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the treatment of mild hypertension study
83. The cost effectiveness of treating all patients with type 2 diabetes with ACE inhibitors
84. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
85. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group
86. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II)
87. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists
88. Class differences in the effects of calcium channel blockers in the rat remnant kidney model
89. Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR
90. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients
91. Preservation of renal function: The spectrum of effects by calcium channel blockers
92. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs
93. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass
94. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study